Ad is loading...
PMAQX
Price
$47.29
Change
-$0.67 (-1.40%)
Updated
Nov 15 closing price
PMBCX
Price
$37.47
Change
-$0.53 (-1.39%)
Updated
Nov 15 closing price
Ad is loading...

PMAQX vs PMBCX

Header iconPMAQX vs PMBCX Comparison
Open Charts PMAQX vs PMBCXBanner chart's image
Principal MidCap R6
Price$47.29
Change-$0.67 (-1.40%)
VolumeN/A
CapitalizationN/A
Principal MidCap C
Price$37.47
Change-$0.53 (-1.39%)
VolumeN/A
CapitalizationN/A
PMAQX vs PMBCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
PMAQX vs. PMBCX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PMAQX is a Buy and PMBCX is a Buy.

FUNDAMENTALS
Fundamentals
PMAQX (29.3B) and PMBCX (29.3B) have equal amount of cash in the bank . PMAQX pays higher dividends than PMBCX: PMAQX (0.10) vs PMBCX (0.00). PMAQX was incepted earlier than PMBCX: PMAQX (8 years) vs PMBCX (18 years). PMAQX (10.10) and PMBCX (10.10) have comparable annual turnover. PMAQX has a lower initial minimum investment than PMBCX: PMAQX (0) vs PMBCX (1000). PMAQX annual gain was more profitable for investors over the last year : 29.42 vs. PMBCX (27.23). PMAQX return over 5 years is better than : 51.36 vs. PMBCX (37.86).
PMAQXPMBCXPMAQX / PMBCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years18 years-
Gain YTD23.34422.132105%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets29.3B29.3B100%
Annual Yield % from dividends0.100.00-
Returns for 1 year29.4227.23108%
Returns for 3 years3.96-2.37-167%
Returns for 5 years51.3637.86136%
Returns for 10 yearsN/A78.00-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WEX179.08-1.83
-1.01%
WEX
EHAB7.35-0.09
-1.21%
Enhabit
BW1.77-0.07
-3.80%
Babcock & Wilcox Enterprises
TTNP3.81-0.19
-4.64%
Titan Pharmaceuticals
ARWR18.57-2.84
-13.26%
Arrowhead Pharmaceuticals